Córdoba, December 1st 2016. In the 17th Annual Meeting of the Spanish Society of Research on Cannabinoids (SEIC), hold on Tenerife (Spain) last week, Vivacell presented the last results on several researches lines:
Santos-Garcia et al. Targeting CB2 and/or PPAR-g receptors with phytocannabinoid derivatives for a neuroprotective therapy in mutant SOD-1 mice, an experimental model of amyotrophic lateral sclerosis.
García et al. Benefits of VCE003.2, a cannabigerol quinone derivative, against neuronal deterioration in experimental models of Parkinson’s disease: possible involvement of PPAR-g activation associated with inflammation.
Nadal et al. Tetrahydrocannabinolic acid is a potent PPARg agonist with neuroprotective activity.
The research has been made in collaboration with Department of Biochemistry and Molecular Biology of Complutense University of Madrid; with Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid; the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid; the Department of Cell Biology, Physiology and Immunology of the University of Córdoba and IMIBIC, as well as PhytoPlant Research SL. Additionally, Vivacell shows the strong commitment with the basic research on cannabinoids as sponsor of the meeting.